.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FG01_Bevacizumab.Bevacizumab .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FG01_Bevacizumab.Bevacizumab| name: | Bevacizumab |
| ATC code: | L01FG01 | route: | intravenous |
| n-compartments | 2 |
Bevacizumab is a recombinant humanized monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby preventing the growth of blood vessels that supply tumors. It is used as an anti-angiogenic therapy for a variety of cancers, including metastatic colorectal cancer, non-small cell lung cancer, renal cell carcinoma, and glioblastoma. Bevacizumab is approved and marketed under the brand name Avastin.
Pharmacokinetic parameters refer to adult cancer patients receiving bevacizumab by intravenous infusion in multiple clinical studies. PK shows linear kinetics and minimal accumulation. Parameters listed are typical for a two-compartment model.
Han, K, et al., & Jin, J (2016). Population pharmacokinetics of bevacizumab in cancer patients with external validation. Cancer chemotherapy and pharmacology 78(2) 341–351. DOI:10.1007/s00280-016-3079-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27329360
Rietveld, PCS, et al., & Koolen, SLW (2024). Intraperitoneal pharmacokinetics of systemic oxaliplatin, 5-fluorouracil and bevacizumab in patients with colorectal peritoneal metastases. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 176 116820–None. DOI:10.1016/j.biopha.2024.116820 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38810398
Li, CSW, et al., & Cronenberger, C (2020). Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin. Cancer chemotherapy and pharmacology 85(3) 487–499. DOI:10.1007/s00280-019-03946-8 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31768697